Molecular analysis in pancreatic adenocarcinoma: a real-world study from high-volume French centres (CAPANCOBIO study)
Few patients with advanced PA had SMA of the tumour. Despite patients with targetable molecular alterations identified, very few patients were treated with targeted therapy and/or included in a clinical trial. It is essential to increase SMA for advanced PA in routine clinical practice to increase the use of targeted therapy and inclusions in clinical trials.
Authors
- Marie Müller
- Guillaume Piessen (ORCID: https://orcid.org/0000-0001-8243-8310)
- Gaël S. Roth (ORCID: https://orcid.org/0000-0001-5822-4320)
- David Tougeron (ORCID: https://orcid.org/0000-0002-8065-9635)
- Camille Evrard (ORCID: https://orcid.org/0000-0003-3147-1350)
- Vincent Hautefeuille (ORCID: https://orcid.org/0000-0003-2735-6448)
- Hélène Trelohan
- O. Bouché
- Mathias Brügel (ORCID: https://orcid.org/0000-0001-7574-9364)
- Nicolas Williet (ORCID: https://orcid.org/0000-0002-7296-5464)
Institutions
- Inserm (FR)
- Université de Lille (FR)
- Centre Hospitalier Universitaire de Grenoble (FR)
- Université de Poitiers (FR)
- Centre Hospitalier Universitaire Amiens-Picardie (FR)
- Centre Hospitalier Universitaire de Reims (FR)
- Institute Cancer De La Loire Lucien Neuwirth (FR)
- Centre Hospitalier de la Côte Basque (FR)
- Centre Hospitalier de La Rochelle (FR)
- Nutrition-Génétique et Exposition aux Risques Environnementaux (FR)
- La Rochelle Université (FR)
- Université Grenoble Alpes (FR)
- Université de Lorraine (FR)
- Université de Reims Champagne-Ardenne (FR)
Publication Details
- Journal
- ESMO Gastrointestinal Oncology
- Published
- 2025-02-12
- DOI
- https://doi.org/10.1016/j.esmogo.2025.100142
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00